Getting to Know the Facts About Roivant Sciences

Shares of Roivant Sciences have moved -1.0% today, and are now trading at a price of $10.69. In contrast, the S&P 500 index saw a -0.0% change. Today's trading volume is 19,405,106 compared to the stock's average volume of 6,795,906.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. Based in London, United Kingdom the company has 908 full time employees and a market cap of $7,896,937,472.

The company is now trading -35.87% away from its average analyst target price of $16.67 per share. The 9 analysts following the stock have set target prices ranging from $12.0 to $20.0, and on average give Roivant Sciences a rating of buy.

Over the last 52 weeks, ROIV stock has risen 16.4%, which amounts to a -9.8% difference compared to the S&P 500. The stock's 52 week high is $13.24 whereas its 52 week low is $8.24 per share. Based on Roivant Sciences's average net margin growth of 19.3% over the last 4 years, its core business is on track for profitability and its strong stock performance may continue in the long term.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%)
2023 124,795 4,348,926
2022 61,280 -1,009,030 -1647
2021 55,286 -845,262 -1529
2020 23,795 -809,234 -3401
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.